Predictive Oncology Inc. Faces Potential Nasdaq Delisting On June 9, 2025, Predictive Oncology Inc. announced it received a notification from The Nasdaq Stock Market LLC regarding its failure to comply with the minimum $2.5 million stockholders' equity requirement for continued listing on the Nasdaq Capital Market. As a result, Nasdaq has moved to delist the company's securities. Predictive Oncology had previously submitted a compliance plan but was unable to meet the required standards within the 180-day extension period. The company has appealed the decision, which temporarily halts the delisting process pending a decision from Nasdaq's Hearings Panel. The panel has the authority to grant an extension of up to 180 days, but there is no guarantee that the appeal will be successful. Predictive Oncology is actively exploring all options to meet the listing requirements.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。